Literature DB >> 10570426

Second primary tumors in patients with cutaneous malignant melanoma.

S Bhatia1, L Estrada-Batres, T Maryon, M Bogue, D Chu.   

Abstract

BACKGROUND: Several studies report coexistent or subsequent primary tumors (SPT) among patients with malignant melanoma (MM), with the rate of incidence ranging from 1.5-20% depending on the sample size and the length and completeness of follow-up.
METHODS: The authors followed a cohort of patients with cutaneous MM who were diagnosed and treated at the City of Hope National Medical Center to determine the incidence rate of SPT and associated risk factors. Five hundred eighty-five patients (median age at diagnosis, 43 years) were diagnosed and treated for MM between 1952 and 1996 and followed for a median of 6.5 years (range, 0.0-37.0 years). Ninety-six percent of the cohort had been treated by surgery alone.
RESULTS: Thirty-seven patients developed an SPT. These included skin cancers (n = 23), carcinoma of the urinary bladder, breast carcinoma, and lymphoma (n = 3 each), lung carcinoma and prostate carcinoma (n = 2 each), and cervical carcinoma (n = 1). The estimated cumulative rate of incidence after MM was 5% at 5 years for any SPT, 3.7% for a second skin cancer, and 1.1% for a second solid tumor. Overall, the current cohort of MM patients was found to be at an increased risk for developing a subsequent melanoma (standardized incidence ratio [SIR], 4.5; 95% confidence interval [95% CI], 1.2-10.0) when compared with the general population. Older men (age > 50 years at the time of diagnosis of MM) were at an increased risk of developing subsequent bladder carcinoma (SIR, 6.4; 95% CI, 1.2-15.7).
CONCLUSIONS: Patients diagnosed with MM are at an increased risk of developing subsequent MM and bladder carcinoma. Issues to be addressed in future studies include interactions between environmental exposures and genetic susceptibility and the identification of individuals at increased risk. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Year:  1999        PMID: 10570426     DOI: 10.1002/(sici)1097-0142(19991115)86:10<2014::aid-cncr19>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  p16 immunohistochemistry of multiple primary melanomas as screening to identify Familial Melanoma Syndrome.

Authors:  Giovanni Ponti; Gabriele Luppi; Lorena Losi; Anna Maria Cesinaro; Giuliana Sartori; Antonio Maiorana; Giovanni Pellacani; Caterina Longo; Elisa Boni; Patrizia Pepe; Alberto Giannetti; Stefania Seidenari; Maria Teresa Landi
Journal:  Int J Dermatol       Date:  2011-06-15       Impact factor: 2.736

Review 2.  Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.

Authors:  Balazs I Bodai; Phillip Tuso
Journal:  Perm J       Date:  2015

3.  Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas.

Authors:  Rajmohan Murali; Chris Goumas; Anne Kricker; Lynn From; Klaus J Busam; Colin B Begg; Terence Dwyer; Stephen B Gruber; Peter A Kanetsky; Irene Orlow; Stefano Rosso; Nancy E Thomas; Marianne Berwick; Richard A Scolyer; Bruce K Armstrong
Journal:  Ann Surg Oncol       Date:  2011-09-13       Impact factor: 5.344

4.  Coexistent metastatic melanoma of the kidney with unknown primary and renal cell carcinoma.

Authors:  Maulik Dhandha; Melinda B Chu; John M Richart
Journal:  BMJ Case Rep       Date:  2012-12-14

5.  Clinical characteristics of cutaneous melanoma and second primary malignancies in a dutch hospital-based cohort of cutaneous melanoma patients.

Authors:  Haike M J van der Velden; Michelle M van Rossum; Willeke A M Blokx; Jan B M Boezeman; Marie-Jeanne P Gerritsen
Journal:  Dermatol Res Pract       Date:  2009-12-31

6.  Risk of subsequent primary tumor development in melanoma patients.

Authors:  Veronika Tóth; Zsófia Hatvani; Beáta Somlai; Judit Hársing; János F László; Sarolta Kárpáti
Journal:  Pathol Oncol Res       Date:  2013-05-17       Impact factor: 3.201

7.  Appearance of malignant melanoma after a non-cutaneous cancer diagnosis.

Authors:  Ugo Bottoni; Rita Clerico; Giovanni Paolino; Marina Ambrifi; Cecilia Luci; Paola Corsetti; Stefano Calvieri
Journal:  Ecancermedicalscience       Date:  2013-05-07

8.  Identifying related cancer types based on their incidence among people with multiple cancers.

Authors:  Chris D Bajdik; Zenaida U Abanto; John J Spinelli; Angela Brooks-Wilson; Richard P Gallagher
Journal:  Emerg Themes Epidemiol       Date:  2006-11-08

9.  Modification of second cancer risk after malignant melanoma by parental history of cancer.

Authors:  H Zhang; J Lorenzo Bermejo; J Sundquist; K Hemminki
Journal:  Br J Cancer       Date:  2008-07-15       Impact factor: 7.640

10.  Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland.

Authors:  D B McKenna; D Stockton; D H Brewster; V R Doherty
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.